Molecular imaging of fibrin in a breast cancer xenograft mouse model

Investigative Radiology

Volumn 47, Issue 10, 2012, Pages 553-558

  Uppal, Ritika ^a   Medarova, Zdravka ^a   Farrar, Christian T ^a   Dai, Guangping ^a   Moore, Anna ^a   Caravan, Peter ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

breast cancer; EP 2104R; fibrin; gadolinium; tumor stroma

Indexed keywords

CONTROL LINEAR PEPTIDE; EP 2104R; FIBRIN; FIBRIN ANTIBODY; GADOLINIUM PENTETATE MEGLUMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BOLUS INJECTION; BREAST CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; FIBRIN DEPOSITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; MOLECULAR PROBE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; STEADY STATE; XENOGRAFT;

EID: 84866317301     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31825dddfb     Document Type: Article

References (53)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de l'Hotel-Dieu de Paris, Bailliere JB, Ed., New Sydenham Society, London: 1865;3:654-712.
2. Schuh AC, Keating SJ, Monteclaro FS, et al. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature. 1990;346:756-760.
3. Dolberg DS, Hollingsworth R, Hertle M, et al. Wounding and its role in RSV-mediated tumor formation. Science. 1985;230:676-678. (Pubitemid 16190963)
4. Palumbo JS, Degen JL. Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis. Thromb Res. 2007;120(suppl 2):S22-S28. (Pubitemid 350101770)
5. Bardos H, Molnar P, Csecsei G, et al. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis. 1996;7:536-548. (Pubitemid 26294883)
6. Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost. 1993;69: 406-414. (Pubitemid 23146431)
7. Dvorak HF, Nagy JA, Berse B, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci. 1992;667:101-111. (Pubitemid 23061569)
8. Cavanaugh PG, Sloane BF, Honn KV. Role of the coagulation system in tumor-cellYinduced platelet aggregation and metastasis. Haemostasis. 1988; 18:37-46.
9. Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987;18:275-284. (Pubitemid 17051260)
10. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124:58SY68S.
11. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrino-gen as an extracellular matrix protein. Ann N Y Acad Sci. 2001;936:406-425. (Pubitemid 32613924)
12. Costantini V, Zacharski LR, Memoli VA, et al. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res. 1991; 51:349-353.
13. Brown LF, Van de Water L, Harvey VS, et al. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol. 1988;130:455-465. (Pubitemid 18091373)
14. Dvorak HF, Harvey VS, Estrella P, et al. Fibrin containing gels induce angio-genesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987;57:673-686. (Pubitemid 18031786)
15. Lee JH, Ryu KW, Kim S, et al. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumor. Hepatogastroenterology. 2004; 51:1860-1863. (Pubitemid 39389798)
16. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96: 3302-3309.
17. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cellYmediated elimination of tumor cells. Blood. 2005;105:178-185. (Pubitemid 40053080)
18. Flacke S, Fischer S, Scott MJ, et al. Novel MRI contrast agent for molecular imaging of fibrin implications for detecting vulnerable plaques. Circulation. 2001;104:1280-1285. (Pubitemid 32848118)
19. Winter PM, Caruthers SD, Yu X, et al. Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med. 2003;50:411-416. (Pubitemid 36950862)
20. Winter PM, Cai K, Chen J, et al. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med. 2006;56:1384-1388. (Pubitemid 44865324)
21. Nair S, Kolodziej AF, Bhole G, et al. Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. Angew Chem Int Ed Engl. 2008; 47:4918-4921.
22. Overoye-Chan K, Koerner S, Looby RJ, et al. EP-2104R: a fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc. 2008;130:6025-6039. (Pubitemid 351620850)
23. Pan D, Senpan A, Caruthers SD, et al. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun (Camb). 2009;3234-3236.
24. Zhang Z, Kolodziej AF, Qi J, et al. Effect of peptide-chelate architecture on metabolic stability of peptide-based MRI contrast agents. New J Chem. 2010; 2010:611-616.
25. Pan D, Caruthers SD, Senpan A, et al. Synthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus. J Am Chem Soc. 2011;133:9168-9171.
26. Zhang Z, Kolodziej AF, Greenfield MT, et al. Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity. Angew Chem Int Ed Engl. 2011;50:2621-2624.
27. Pilch J, Brown DM, Komatsu M, et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA. 2006;103:2800-2804.
28. Ye F, Wu X, Jeong EK, et al. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug Chem. 2008;19:2300-2303.
29. Tan M, Wu X, Jeong EK, et al. Peptide-targeted nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacromolecules. 2010;11:754-761.
30. Tan M, Wu X, Jeong EK, et al. An effective targeted nanoglobular manganese (II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix. Mol Pharmacol. 2010;7:936-943.
31. Duerschmied D, Meibetaner M, Peter K, et al. Molecular magnetic resonance imaging allows the detection of activated platelets in a new mouse model of coronary artery thrombosis. Invest Radiol. 2011;46:618-623.
32. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697-704.
33. Uppal R, Catana C, Ay I, et al. Bimodal thrombus imaging: simultaneous PET/MR imaging with a fibrin-targeted dual PET/MR probe-feasibility study in rat model. Radiology. 2011;258:812-820.
34. Uppal R, Ay I, Dai G, et al. Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke. 2010;41:1271-1277.
35. Stracke CP, Katoh M, Wiethoff AJ, et al. Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent. Stroke. 2007; 38:1476-1481. (Pubitemid 46684148)
36. Spuentrup E, Katoh M, Wiethoff AJ, et al. Molecular magnetic resonance imaging of pulmonary emboli with a fibrin-specific contrast agent. Am J Respir Crit Care Med. 2005;172:494-500. (Pubitemid 41117396)
37. Spuentrup E, Katoh M, Buecker A, et al. Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol. 2007;42:586-595. (Pubitemid 47051836)
38. Spuentrup E, Fausten B, Kinzel S, et al. Molecular magnetic resonance imaging of atrial clots in a swine model. Circulation. 2005;112:396-399. (Pubitemid 41022081)
39. Spuentrup E, Buecker A, Katoh M, et al. Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation. 2005;111:1377-1382. (Pubitemid 40396803)
40. Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008;18:1995-2005.
41. Botnar RM, Buecker A, Wiethoff AJ, et al. Invivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation. 2004;110:1463-1466. (Pubitemid 39238024)
42. Sirol M, Fuster V, Badimon JJ, et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation. 2005;112:1594-1600. (Pubitemid 41324521)
43. Katoh M, Haage P, Wiethoff AJ, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150.
44. Morelli JN, Runge VM, Williams JM, et al. Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model. Invest Radiol. 2011;46:169-177.
45. Uppal R, Medarova Z, Farrar C, et al. Molecular MR imaging of fibrin in tumors. Proc Int Soc Magn Reson Med. 2009:1250.
46. Simpson RJ. Proteins and Proteomics: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2003.
47. Kolodziej A, Nair SA, Graham PB, et al. Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging. Bioconjug Chem. 2012;23:548-556.
48. Caravan P, Farrar CT, Frullano L, et al. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium-and manganese-based T1 contrast agents. Contrast Media Mol Imaging. 2009;4:89-100.
49. Nieminen MT, Rieppo J, Silvennoinen J, et al. Spatial assessment of articular cartilage proteoglycans with Gd-DTPAYenhanced T1 imaging. Magn Reson Med. 2002;48:640-648.
50. Essig M, Weber MA, von Tengg-Kobligk H, et al. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging. 2006;17:89-106. (Pubitemid 46050572)
51. Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging. 2004;20:138-144. (Pubitemid 38857527)
52. Orth RC, Bankson J, Price R, et al. Comparison of single-and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents. Magn Reson Med. 2007; 58:705-716. (Pubitemid 47556875)
53. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232. (Pubitemid 29463104)